Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2023-07, Vol.25 (7), p.1964-1972
• Main Authors: Aronson, Ronnie, Biester, Torben, Leohr, Jennifer, Pollom, Robyn, Linnebjerg, Helle, LaBell, Elizabeth Smith, Zhang, Qianyi, Coutant, David E., Danne, Thomas
• Format: Article
• Language: English
• Subjects: Adolescent; Adolescents; Adult; Age groups; Blindness; Blood Glucose; Child; Children; Cross-Over Studies; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Glucose; Glucose - therapeutic use; Humans; Hypoglycemic Agents - adverse effects; Insulin; Insulin Lispro - pharmacokinetics; Insulin Lispro - therapeutic use; insulin therapy; pharmacodynamics; Pharmacokinetics; Postprandial Period; Teenagers; type 1 diabetes mellitus; ultra rapid insulin
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.15063

Aim This study compared the pharmacokinetics, glucodynamics and tolerability following single subcutaneous doses of ultra rapid lispro (URLi) versus Humalog in children (6‐11 years), adolescents (12‐17 years) and adults (18‐64 years) with type 1 diabetes mellitus (T1D). Materials and Methods The study was a randomized, two‐period, subject‐ and investigator‐blind, crossover design in participants with T1D. Participants received a 0.2 U/kg bolus dose immediately before a liquid mixed meal tolerance test. Insulin lispro and glucose concentrations were measured. Results The study included 13 children, 14 adolescents and 15 adults. Consistently across the age groups, onset of appearance was 4‐5 min faster, the early 50% tmax was reduced by 7‐13 min, and exposure in the first 15 min was increased by 3.5‐6.5‐fold following URLi compared with Humalog (all p